ANAPLASTIC ASTROCYTOMA

This study tests a new way to treat aggressive brain cancers that have come back after standard therapy. It combines a targeted drug called cetuximab, given directly into the brain's blood vessels, with a second round of radiation. The goal is to see if this approach can safely s…

This study follows children who have already taken dabrafenib and/or trametinib for certain brain tumors. Researchers will monitor side effects and track growth over time. The goal is to understand the long-term safety of these medications in young patients.

This study tests whether giving two cancer drugs (cetuximab and bevacizumab) directly into the brain's blood vessels each month is safe and can shrink or control relapsed brain tumors in people under 22. About 20 participants with specific types of glioma will receive the treatme…

This study tests a new gene therapy (HSV-tk) plus valacyclovir, given together with radiation and chemotherapy, for people newly diagnosed with aggressive brain cancers called glioblastoma or anaplastic astrocytoma. The goal is to see if this combination improves survival and slo…

This study tests whether adding two different drug combinations after radiation can help children and young adults with high-grade gliomas (including DIPG) live longer. One group receives ribociclib plus everolimus, and another receives ribociclib plus temozolomide, based on the …

This study tests a treatment for people with aggressive brain tumors (glioblastoma, anaplastic astrocytoma, or gliosarcoma) that have come back or are newly diagnosed. The treatment combines a genetically modified herpes virus (M032) that delivers an immune-boosting protein (IL-1…

This early-phase study tests an oral drug called ONC206 in 102 adults with brain tumors that have come back or are rare. The main goal is to find the safest dose and understand side effects. Participants take the drug by mouth on a weekly schedule, and researchers monitor for any…

This early-phase study tests a new two-drug combination for adults whose high-grade glioma (a type of brain cancer) has come back after standard treatment. The drugs are a low, continuous dose of temozolomide (a chemotherapy pill) plus abexinostat (an experimental drug). The main…

This study tests a drug called lorlatinib in children (ages 1-21) with a newly diagnosed, aggressive brain tumor that has a specific genetic change (ALK or ROS1 fusion). The goal is to see if the drug can shrink or control the tumor and to check its safety when given alone or wit…

This study aims to analyze the genetic makeup of brain tumors in children, teens, and young adults (ages 1 to 39) newly diagnosed with high-grade glioma, including a type called DIPG. By identifying specific genetic changes in each tumor, researchers hope to match patients with m…